Ligand Pharmaceuticals Incorporated (LGND)

Ligand Pharmaceuticals Incorporated (LGND) Analyst/Investor Day Transcript...

Introduces 2026 full year revenue guidance of $245 million to $285 million, an approximately 15% increase in core revenue growth over 2025, royalty revenue of $200 to $225 million, a 40% increase over...

Exploring Tweedy Browne (Trades, Portfolio)'s Recent 13F Filing and Investment Adjustments Tweedy Browne (Trades, Portfolio) recently submitted its 13F filing...

Delaware-based Ashford Capital Management sold 58,097 shares of Ligand Pharmaceuticals for an estimated $8.9 million in the third quarter. The transaction value equaled about 1% of 13F reportable asse...

Envestnet Asset Management Inc. boosted its holdings in Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) by 2.9% during the undefined quarter, according to the company in its most recent disclosure ...

Insights from Private Capital (Trades, Portfolio)'s Third Quarter 2025 13F Filing Private Capital (Trades, Portfolio) recently submitted its 13F filing for the...

Ligand Pharmaceuticals (LGND) continues to deliver strong returns, with shares up approximately 74% since my last 'Buy' rating in June 2025. LGND's attractive royalty-based business model remains a ke...

Ligand Pharmaceuticals Incorporated ( LGND ) Q3 2025 Earnings Call November 6, 2025 8:30 AM EST Company Participants Melanie Herman Todd Davis - CEO & Director Lauren Hay Octavio Espinoza - Chief Fina...

Third quarter performance driven by strong portfolio royalty revenue growth of  47% 2025 full year revenue guidance increased to $225 million - $235 million (previously $200 million - $225 million) an...

JUPITER, Fla., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza wi...